Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial

Table 1 Baseline characteristics of subjects

	Placebo (n = 6)	Sitagliptin (n = 6)
Demographics
Age (yr)	54.7 ± 9.8	56.7 ± 9.9
Gender - male, n (%)	2 (33)	3 (50)
White, n (%	6 (100	5 (83)
Weight (kg)	105.8 ± 23.5	100.4 ± 28.7
BMI (kg/m2)	37.4 ± 4.7	35.9 ± 6.6
Diabetes duration (yr)1	6.0 (5.0, 6.0)	6.5 (5.0, 23.0)
NASH Duration (yr)1	4.0 (1.0, 4.0)	1.3 (0.1, 2.0)
Biochemical profile
HbA1C (%)	8.2 ± 0.9	7.9 ± 1.0
HOMA-IR	3.5 ± 2.2	3.4 ± 1.2
Fasting glucose (mmol/L)	11.3 ± 4.9	8.1 ± 3.1
Fasting insulin (pmol/L)	165 ± 134	168 ± 63
AST (IU/L)	39 ± 19	44 ± 22
ALT (IU/L)	46 ± 36	72 ± 50
Alkaline phosphatase (IU/L)	85 ± 34	93 ± 41
GGT (IU/L)	100 ± 98	164 ± 182
Triglycerides (mmol/L)	2.33 ± 2.00	2.80 ± 1.64
HDL-C (mmol/L)	1.10 ± 0.34	1.12 ± 0.46
LDL-C (mmol/L)	1.61 ± 0.71	1.42 ± 0.97
Free fatty acids (μmol/L)	645 ± 195	559 ± 158
Platelet aggregation (PRU)	292 ± 37	236 ± 28
Histologic profile
Fibrosis	2.2 ± 0.8	2.2 ± 1.0
NAS	4.2 ± 1.5	3.8 ± 0.8
Steatosis	1.8 ± 0.8	1.8 ± 0.8
Lobular Inflammation	1.2 ± 0.4	1.0 ± 0
Ballooning	1.2 ± 0.4	1.0 ± 0
MRI
Hepatic fat (%)	21.9 ± 10.6	19.0 ± 9.7
SAAT (%)	40.5 ± 7.1	38.0 ± 22.0
VAT (%)	30.5 ± 3.4	26.8 ± 11.6
Left thigh fat (%)	37.8 ± 9.9	39.5 ± 15.8

¹Data are presented as median (Q1, Q3). Data are presented as mean ± SD, unless otherwise specified. ALT: Alanine aminotransferase; AST: Aspartate transferase; BMI: Body mass index; HbA1C: Hemoglobin A1C; HOMA-IR: Homeostasis model of assessment for insulin resistance; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol; NAS: Non-alcoholic fatty liver disease activity score; NASH: Non-alcoholic steatohepatitis; MRI: Magnetic resonance imaging; PRU: Platelet reaction units; SAAT: Subcutaneous abdominal adipose tissue; VAT: Visceral adipose tissue.